ATNM - Actinium Pharmaceuticals, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue----
Cost of Revenue----
Gross Profit----
Operating Expenses
Research Development17,094.77817,719.85517,828.28713,501.895
Selling General and Administrative6,732.5449,190.9339,019.19411,274.404
Non Recurring----
Others----
Total Operating Expenses23,827.32226,910.78826,847.48124,829.764
Operating Income or Loss-23,827.322-26,910.788-26,847.481-24,829.764
Income from Continuing Operations
Total Other Income/Expenses Net173.359309.5532,525.7573,804.45
Earnings Before Interest and Taxes-23,827.322-26,910.788-26,847.481-24,829.764
Interest Expense---5.007-7.868
Income Before Tax-23,653.963-26,601.235-24,321.724-21,025.314
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-23,653.963-26,601.235-24,321.724-21,025.314
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-23,653.963-26,601.235-24,321.724-21,025.314
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-23,653.963-26,601.235-24,321.724-21,025.314